enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of “Buy” by Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has been given an average recommendation of “Buy” by the ten brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $25.22.

Several equities research analysts have recently issued reports on the company. Piper Sandler assumed coverage on enGene in a report on Tuesday, February 18th. They issued an “overweight” rating and a $26.00 target price on the stock. Raymond James started coverage on enGene in a research report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 target price for the company. Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research note on Monday, November 18th. Morgan Stanley dropped their price objective on shares of enGene from $37.00 to $34.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th. Finally, UBS Group downgraded shares of enGene from a “buy” rating to a “neutral” rating and lowered their price target for the company from $34.00 to $7.00 in a report on Friday, February 14th.

Hedge Funds Weigh In On enGene

Several hedge funds have recently bought and sold shares of the business. Vontobel Holding Ltd. purchased a new stake in shares of enGene during the fourth quarter valued at $69,000. Jane Street Group LLC bought a new stake in enGene during the 4th quarter valued at about $93,000. Toronto Dominion Bank purchased a new stake in enGene in the 4th quarter valued at about $97,000. Cubist Systematic Strategies LLC grew its stake in enGene by 15.7% in the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock worth $102,000 after acquiring an additional 2,080 shares in the last quarter. Finally, Corton Capital Inc. purchased a new position in shares of enGene during the fourth quarter worth approximately $157,000. Institutional investors own 64.16% of the company’s stock.

enGene Stock Up 0.9 %

NASDAQ ENGN opened at $5.40 on Friday. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene has a 12 month low of $4.42 and a 12 month high of $18.40. The stock’s 50 day moving average is $6.51 and its 200 day moving average is $7.12. The stock has a market cap of $275.28 million, a PE ratio of -9.31 and a beta of -0.61.

enGene (NASDAQ:ENGN) last issued its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. Research analysts predict that enGene will post -1.56 EPS for the current fiscal year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.